ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
On April 13, 2026, ALX Oncology Holdings Inc. announced the appointment of Jeff Knight as Chief Development and Operating Officer. Mr. Knight, 55, brings over 30 years of biopharmaceutical experience, having previously served as Chief Development and Operating Officer at Crinetics Pharmaceuticals and in senior roles at Poseida Therapeutics, Halozyme Therapeutics, Amgen, and Onyx Pharmaceuticals. His background includes significant expertise in oncology clinical development and regulatory affairs from his time at Genentech. Under the terms of his employment, Mr. Knight will receive an annual base salary of $565,000 and is eligible for a target annual cash bonus of 40% of his base salary. Additionally, he was granted a stock option to purchase 800,000 shares of common stock under the companyβs 2025 Inducement Equity Incentive Plan, vesting over four years. The company highlighted that Mr. Knight's leadership will be critical as ALX Oncology approaches several clinical catalysts for its evorpacept and ALX2004 programs over the next 12 to 18 months.